Akoya Biosciences (NASDAQ:AKYA – Get Rating) had its price target decreased by investment analysts at Piper Sandler from $18.00 to $14.00 in a report released on Sunday, The Fly reports. Piper Sandler’s price target indicates a potential upside of 40.99% from the stock’s previous close.
Several other equities research analysts have also commented on AKYA. Zacks Investment Research lowered shares of Akoya Biosciences from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 17th. Morgan Stanley cut their price target on shares of Akoya Biosciences from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 15th.
Akoya Biosciences stock traded up $0.53 during midday trading on Friday, reaching $9.93. The company’s stock had a trading volume of 52,511 shares, compared to its average volume of 67,212. Akoya Biosciences has a fifty-two week low of $8.02 and a fifty-two week high of $23.44. The company has a quick ratio of 4.76, a current ratio of 3.98 and a debt-to-equity ratio of 0.31. The company has a market cap of $373.27 million and a P/E ratio of -6.99. The business has a 50-day simple moving average of $10.70 and a 200-day simple moving average of $11.81.
Several institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. increased its holdings in shares of Akoya Biosciences by 12.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 67,401 shares of the company’s stock valued at $741,000 after acquiring an additional 7,243 shares during the period. Parkman Healthcare Partners LLC increased its holdings in shares of Akoya Biosciences by 20.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 150,321 shares of the company’s stock valued at $1,652,000 after acquiring an additional 25,321 shares during the period. Candriam Luxembourg S.C.A. boosted its stake in shares of Akoya Biosciences by 216.7% during the first quarter. Candriam Luxembourg S.C.A. now owns 159,300 shares of the company’s stock worth $1,751,000 after buying an additional 109,000 shares during the period. Vanguard Group Inc. boosted its stake in shares of Akoya Biosciences by 3.8% during the first quarter. Vanguard Group Inc. now owns 700,823 shares of the company’s stock worth $7,702,000 after buying an additional 25,845 shares during the period. Finally, BlackRock Inc. boosted its stake in shares of Akoya Biosciences by 1.4% during the first quarter. BlackRock Inc. now owns 777,001 shares of the company’s stock worth $8,538,000 after buying an additional 10,737 shares during the period. 39.90% of the stock is currently owned by institutional investors and hedge funds.
Akoya Biosciences Company Profile (Get Rating)
Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. It offers single-cell resolution with spatial context that provides a wealth of information to visualize tissue organization and disease pathology on a molecular level to understand disease progression and treatment response.
- Get a free copy of the StockNews.com research report on Akoya Biosciences (AKYA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.